Correction to: Wensing AM, Calvez V, Ceccherini-Silberstein F, et al. 2025 update of the drug resis-
tance mutations in HIV-1. Top Antivir Med. 2025;33(2):457-473. https://www.iasusa.org/wp-content/uploads/2025/05/33-2-457.pdf
From February 26, 2026, through September 18, 2026, a version of the Drug Resistance Mutations Figure
incorrectly and preliminarily included islatravir in the nonnucleoside reverse transcriptase inhibitor (NNRTI)
section. Islatravir is a nucleoside reverse transcriptase translocation inhibitor (NRTTI). The Figure has been
corrected to remove the preliminary version of islatravir from the NNRTI section. Islatravir will be added to
the appropriate section in a future iteration of the Figure.
See also: Wensing AM, Calvez V, Ceccherini-Silberstein F, et al. Current evidence on islatravir drug resistance
and implications for future HIV treatment. Top Antivir Med. 2026;34(3):527-532. https://www.iasusa.org/tam-34-1-wensing/